What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Executive Summary
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.
You may also be interested in...
Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames
$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.